StockNews.com assumed coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Free Report) in a research note issued to investors on Tuesday. The firm issued a sell rating on the biotechnology company’s stock.
Genocea Biosciences Price Performance
Genocea Biosciences has a 52 week low of $0.00 and a 52 week high of $0.00. The stock has a market capitalization of $6,000.00, a price-to-earnings ratio of 0.00 and a beta of 1.61. The company has a quick ratio of 1.35, a current ratio of 1.35 and a debt-to-equity ratio of 0.24.
About Genocea Biosciences
Featured Articles
- Five stocks we like better than Genocea Biosciences
- Where Do I Find 52-Week Highs and Lows?
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- What Does a Stock Split Mean?
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- What is a buyback in stocks? A comprehensive guide for investors
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.